doxorubicin

(redirected from Caelyx)
Also found in: Thesaurus, Medical.
Related to Caelyx: Doxil, Myocet

dox·o·ru·bi·cin

(dŏk′sə-ro͞o′bĭ-sĭn)
n.
An antibiotic, C27H29NO11, obtained from the bacterium Streptomyces peuceticus and used as an anticancer drug.

[Alteration of (hy)d(r)oxy + rubi(domy)cin, antibiotic from which it is derived (Latin rubidus, red, from its red crystals; see rubidium + -mycin).]

doxorubicin

(ˌdɒksəˈruːbəsɪn)
n
an antineoplastic antibiotic used in the treatment of cancer
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.doxorubicin - an antibiotic used as an anticancer drug
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
Translations

doxorubicin

n doxorubicina
References in periodicals archive ?
The EMA also recommended that the use of Johnson & Johnson's Doxil, which is known as Caelyx in Europe, is restricted only to patients that have already started taking it.
She received further chemotherapeutic treatment with Caelyx (liposomal, encapsulated doxyrubicin) and did not achieve any results.
Other important products are Temodar, a treatment for brain tumors; Integrilin for cardiovascular problems; Avelox, a treatment for bacterial infections; Intron A for cancer and viral infections; Subutex for opiate dependence; Caelyx for skin cancer; Cipro, an antibiotic; and Elocon for inflammatory skin conditions.
PolyMASC initiated infringement proceedings against ALZA in the United States in April 2001, for infringement of United States patent Number 6,132,763, based on ALZA's manufacturing and selling of Doxil and Caelyx, PEGylated-liposome products encapsulating the drug doxorubicin.
Continuous supply of medicinal Caelyx and in the structure and the expected number of individual forces specified in Annex no.
M2 PHARMA-September 30, 2010-Janssen to assume CAELYX global marketing rights from Merck(C)2010 M2 COMMUNICATIONS
Burlingame, CA; 650-697-1900) confirmed a Bloomberg report that its wholly-owned subsidiary, PolyMASC Pharmaceuticals, has filed a lawsuit against ALZA Corporation (Palo Alto, CA) for patent infringement based on ALZA's manufacture and sale of its liposomal products, Doxil and Caelyx.
Caelyx,Package - 29: treatment of chronic hepatitis B - adefovirem.